AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06547385
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06547385
Drug: Calcium Levofolinate Hydrateb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06478134
Drug: Trimix tear substitutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.
Trial: NCT04614298
Drug: KHK4827-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC administration
Trial: NCT06483685
Drug: Radiopharmaceuticals drugs
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
Trial: NCT04366518
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Aim 1 will receive a placebo patch versus scopolamine patch.
Trial: NCT05332106
Drug: Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climodien (Bayer plc.)
Trial: NCT06284434
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
Trial: NCT05765747
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
Trial: NCT05573100
Drug: CU06-1004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
Trial: NCT05247125
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg Melatonin pill will be given 1 hour before going to bed.
Trial: NCT05219929
Drug: Tetracycline 500 Mg
RxNorm normalized name: oxytetracycline 500 MG
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg three times daily
Trial: NCT04128462
Drug: MNK-6105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Ornithine Phenylacetate for IV infusion
Trial: NCT04128462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for IV infusion
Trial: NCT04128462
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
Trial: NCT04205136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
Trial: NCT04999605
Drug: AK112 medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
Trial: NCT04922996
Drug: Calcium Dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of calcium dobesilate in different tissues
Trial: NCT05160311
Drug: Optimized Medical Treatment (OMT)
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized Medical Drug Treatment
Trial: NCT04940182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo 2 times a day during 14 full days
Trial: NCT05414552
Drug: ECP
RxNorm normalized name: Ecpirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks
Trial: NCT05041972
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARX788 will be administered by intravenous (IV) infusion every 3 weeks (Q3W).
Trial: NCT05780216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
Trial: NCT04151472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet, three times a day
Trial: NCT05663164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl solution) volume to match all components
Trial: NCT05328024
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD1
Trial: NCT04864717
Drug: Isotretinoin 40 mg po once daily x 6 months
RxNorm normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active intervention
Trial: NCT05158023
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution for subcutaneous injection
Trial: NCT04102436
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Trial: NCT04469062
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04469062
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05275751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pharmacological intervention
Trial: NCT04676711
Drug: GFH312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
Trial: NCT04676711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are planned to be dosed in oral tablet, with single and multiple ascending doses
Trial: NCT04017390
Drug: Placebo Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply placebo foam alone
Trial: NCT05004519
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dexmedetomidine or remifentanil during laparoscopic gastric bypass
Trial: NCT05248646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo s.c. q 4 weeks
Trial: NCT05434299
Drug: TFX05-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFX05-01 for intravenous
Trial: NCT06315101
Drug: Chinese Herbal Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
Trial: NCT05247697
Drug: Placebo oral tablet once daily at bedtime
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05046106
Drug: MLC1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
Trial: NCT05033080
Drug: VX-121/TEZ/D-IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT05033080
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT05033080
Drug: Placebo (matched to ELX/TEZ/IVA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to ELX/TEZ/IVA for oral administration.
Trial: NCT05033080
Drug: Placebo (matched to IVA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to IVA for oral administration.
Trial: NCT04665362
Drug: Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib
Trial: NCT05063968
Drug: XZP-6019 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet is administered orally once on Day 1 and Day 9, respectively
Trial: NCT04772885
Drug: KT-474/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KT-474 or matching placebo oral tablet(s)
Trial: NCT05063968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet is administered orally once on Day 1 and Day 9, respectively
Trial: NCT05063968
Drug: XZP-6019 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet is administered fasted orally once on Day 1
Trial: NCT05063968
Drug: XZP-6019 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet is administered after a high-fat meal orally once on Day 9
Trial: NCT05063968
Drug: XZP-6019 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet is administered orally once daily for 14 Days continuously
Trial: NCT05063968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet is administered orally once daily for 14 Days continuously
Trial: NCT05256810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by SC injection
Trial: NCT05009199
Drug: [18F]MNI-444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-444.
Trial: NCT05359055
Drug: SPH3127 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg once daily on Day 1 and Day 8
Trial: NCT05359055
Drug: SPH3127 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg once daily on Day 1 and Day 12.
Trial: NCT05865171
Drug: IXP
RxNorm normalized name: NovoSeven RT with MixPro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT04692805
Drug: cyanoacrylate glue
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUS-guided injection of cyanoacrylate glue
Trial: NCT04288206
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous normal saline placebo
Trial: NCT06009744
Drug: Low-dose vitamin C and zinc
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
Trial: NCT06009744
Drug: High-dose vitamin C and zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
Trial: NCT05953831
Drug: CDR132L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
Trial: NCT05953831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to CDR132L
Trial: NCT05052710
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive oral doses once daily from Days 2-11.
Trial: NCT05153785
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05930808
Drug: First Test Concor (Fasted)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
Trial: NCT05930808
Drug: First Reference Concor (Fasted)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
Trial: NCT05930808
Drug: First Test Concor (Fed)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
Trial: NCT05930808
Drug: First Reference Concor (Fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
Trial: NCT05217355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected into the Glabellar line
Trial: NCT04658654
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill with inactive ingredients to mimic same appearance of roflumilast capsule
Trial: NCT06026319
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT05418777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of suspension with placebo by mouth every 12 hours for 10 days
Trial: NCT04910815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
Trial: NCT04715022
Drug: Ascorbic acid solution (American Regent Laboratories Inc.)
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.
Trial: NCT00259571
Drug: retarded release phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g daily, given orally QTD
Trial: NCT05412459
Drug: 99mTc-DARPinG3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic test (99mTc-DARPinG3-based SPECT) is used for the assessment of the effect of anticancer therapy.
Trial: NCT00088647
Drug: MST-997
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02844530
Drug: chemotherapy/ immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04748536
Drug: IRL201104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilised powder for reconstitution for IV dosing
Trial: NCT04748536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for IRL201104
Trial: NCT04594733
Drug: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
Trial: NCT04594733
Drug: Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
Trial: NCT04680637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a subcutaneous (SC) injection.
Trial: NCT05653973
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and nitric oxide-dependent dilation
Trial: NCT01561092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT05666687
Drug: MIJ821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIJ821 will be administered as an i.v. infusion
Trial: NCT06110065
Drug: Percutaneous image-guided cryoneurolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
Trial: NCT04778514
Drug: Dual Prevention Pill
RxNorm normalized name: Gas-X Prevention Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single over-encapsulated DPP containing a PrEP tablet and a COC
Trial: NCT04778514
Drug: PrEP and combined oral contraceptive (COC) as two separate tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP tablet and a COC as two separate tablets
Trial: NCT04911062
Drug: Bupivacaine HCI without epinephrine
RxNorm normalized name: bupivacaine / epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg administered via injection into the surgical site.
Trial: NCT06490601
Drug: thalidomide and hydroxyurea
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity.
Trial: NCT05291221
Drug: intratracheal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
Trial: NCT04845035
Drug: Berlin-Frankfurt-Münster Chemotherapy
RxNorm normalized name: Gila monster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
Trial: NCT04845035
Drug: Methotrexate and Cytarabine
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal
Trial: NCT05667779
Drug: QRL-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
Trial: NCT05097768
Drug: Ketorolac 10 Mg Oral Tablet
RxNorm normalized name: ketorolac 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT05097768
Drug: Meloxicam 7.5 mg
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT05097768
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT05097768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be randomly given the medication by mouth 60 min before administering IANB.
Trial: NCT04582305
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
Trial: NCT05754684
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone po three time daily
Trial: NCT06546423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.